Real World Experience of Azacitidine + Venetoclax in AML rigorously following management guidelines from clinical trial.

IF 1.1 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2025-09-29 DOI:10.1159/000548334

Bochra Sedaki, Alexandre Iat, Sami Benachour, Michael Loschi, Karine Risso, Ghada Abichou, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau

{"title":"Real World Experience of Azacitidine + Venetoclax in AML rigorously following management guidelines from clinical trial.","authors":"Bochra Sedaki, Alexandre Iat, Sami Benachour, Michael Loschi, Karine Risso, Ghada Abichou, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau","doi":"10.1159/000548334","DOIUrl":null,"url":null,"abstract":"<p><p>Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to VIALE-A study. We report here our single center experience using AZA + VEN rigorously following management guidelines from the VIALE-A study, applied to a real-life population. Forty-two AML patients were analyzed. CR/CRi/MLFS rate was 73,8 % after 1 cycle with 51% CR/CRi and 80,9% after 2 cycles. Median overall survival was 18 months [95% CI, 10.3-25.7]. Our retrospective study showed that rigorous use of AZA + VEN in real-world setting was associated with results close to clinical trial observations. We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in real-world.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-13"},"PeriodicalIF":1.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548334","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to VIALE-A study. We report here our single center experience using AZA + VEN rigorously following management guidelines from the VIALE-A study, applied to a real-life population. Forty-two AML patients were analyzed. CR/CRi/MLFS rate was 73,8 % after 1 cycle with 51% CR/CRi and 80,9% after 2 cycles. Median overall survival was 18 months [95% CI, 10.3-25.7]. Our retrospective study showed that rigorous use of AZA + VEN in real-world setting was associated with results close to clinical trial observations. We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in real-world.

查看原文本刊更多论文

阿扎胞苷+ Venetoclax治疗AML的真实世界经验严格遵循临床试验的管理指南。

阿扎胞苷+ venetoclax是急性髓系白血病不适合强化化疗的新标准治疗方案。这种组合与血液毒性和某些药物相互作用有关。现实世界的研究表明，与VIALE-A研究相比，结果和结果有所下降。我们在此报告我们使用AZA + VEN的单中心经验，严格遵循VIALE-A研究的管理指南，应用于现实生活中的人群。对42例AML患者进行分析。1个疗程后CR/CRi/MLFS为73.8%，2个疗程后CR/CRi为51%，MLFS为809%。中位总生存期为18个月[95% CI， 10.3-25.7]。我们的回顾性研究表明，在现实环境中严格使用AZA + VEN与临床试验观察结果接近。我们展示了严格遵循AZA+VEN剂量的必要性，以及在临床试验中编辑的毒性指南和实践建议，即使在现实世界中也是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.